ARTICLE | Clinical News
Versicor begins anidulafungin Phase II study
June 26, 2001 7:00 AM UTC
VERS began an open-label U.S. Phase II trial of its anidulafungin (formerly V-Echinocandin), an inhibitor of fungal cell wall synthesis, in 120 hospitalized patients diagnosed with invasive candiadias...